Angiosarcoma of the visceral organs: A morphological, immunohistochemical, and C-MYC status analysis

Zhang, Jiaojiao; Gong, Hai‐Bin; Wang, Yuanyuan; Zhang, Guanjun

doi:10.1016/j.prp.2022.154118

Cited by 4 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Angiosarcoma is a rare yet aggressive mesenchymal tumor of endothelial origin [ 5 ]. There are several specific challenges associated with the clinical development of therapeutics for this disease, such as absence of prior clinical studies, and a lack of information on disease mechanisms and progression [ 6 , 7 ].…”

Section: To the Editormentioning

confidence: 99%

Generation of sarconoids from angiosarcoma patients as a systematic-based rational approach to treatment

Jung,

Byeon,

Kim

et al. 2024

J Hematol Oncol

View full text Add to dashboard Cite

Angiosarcoma is a rare subtype of malignant neoplasm originating from vascular or lymphatic endothelial cells; its low incidence has posed significant challenges for comprehensive investigations into its pathogenic mechanisms and the development of innovative treatment modalities through in vitro and in vivo models. Recent endeavors spearheaded by patient-partnered research initiatives have aimed to elucidate the intricacies of angiosarcomas by leveraging biological omics approaches, with the overarching objective of enhancing prognostic indicators and therapeutic options for this uncommon pathology. To bridge the gap between preclinical research and translational applications, we engineered angiosarcoma-derived organoids from surgically resected primary tumors, hereafter referred to as “sarconoids,” as a proof-of-concept model. A novel protocol for the establishment of these sarconoids has been developed and validated. To ensure that the sarconoids faithfully recapitulate the heterogeneity and complexities of the patients’ original tumors, including transcriptomic signatures, cell-type specificity, and morphological traits, exhaustive histological and transcriptomic analyses were conducted. Subsequently, we expanded the scope of our study to include an evaluation of a sarconoid-based drug screening platform; for this purpose, a drug library (AOD IX), supplied by the National Cancer Institute’s Developmental Therapeutics Program, was screened using 96-well plates. Our findings suggest that sarconoids can be reliably generated from angiosarcoma patient-derived tissues and can serve as accurate models for evaluating therapeutic responses, thereby holding far-reaching implications for translational research and clinical applications aimed at advancing our understanding and treatment of angiosarcoma.

show abstract

Section: To the Editormentioning

confidence: 99%

Generation of sarconoids from angiosarcoma patients as a systematic-based rational approach to treatment

Jung,

Byeon,

Kim

et al. 2024

J Hematol Oncol

View full text Add to dashboard Cite

show abstract

“…MYC amplification or high expression is seen in less than 10% of sporadic angiosarcomas [88]; it is much more common in secondary angiosarcoma related to breast cancer and lymphedema [88]. However, recent studies have detected MYC amplification in almost one-third of primary breast angiosarcomas [90] and 25% of visceral angiosarcomas [91]. Particularly in younger patients, CIC fusions have been described, and the presence of CIC alterations is associated with inferior diseasefree survival [88].…”

Section: Angiosarcomamentioning

confidence: 99%

Mesenchymal Tumors of the Gastrointestinal Tract—Beyond GIST—A Review

Gama,

Oliveira

2024

Gastrointestinal Disorders

View full text Add to dashboard Cite

Sarcomas are rare lesions and encompass a wide variety of entities, depending on their nature. In recent years new entities have been described and new knowledge, especially that provided by molecular studies, has been increasing. This makes it very difficult to be updated with all the described entities, since only some of the centers have the desired ancillary studies for the correct diagnosis. Some lesions are extremely rare and may appear once or twice during the lifetime of a general pathologist. When we refer to sarcomas of the gastrointestinal tract, the gastrointestinal stromal tumor (GIST) is the most well-known lesion that the pathologist will most frequently find in daily practice. This paper aims to comprehensively review the sarcomas associated with the gastrointestinal tract, emphasizing histopathology and going beyond GIST. This review highlights the histopathology of rare types of sarcomas so it may increase awareness of common and rare lesions, prompting an easy and effective diagnosis.

show abstract

MYC amplification in angiosarcoma depends on etiological/clinical subgroups – Diagnostic and prognostic value

Hogeboom-Gimeno¹,

Ravensteijn²,

Desar³

et al. 2023

Annals of Diagnostic Pathology

View full text Add to dashboard Cite

Angiosarcoma of the visceral organs: A morphological, immunohistochemical, and C-MYC status analysis

Cited by 4 publications

References 25 publications

Generation of sarconoids from angiosarcoma patients as a systematic-based rational approach to treatment

Generation of sarconoids from angiosarcoma patients as a systematic-based rational approach to treatment

Mesenchymal Tumors of the Gastrointestinal Tract—Beyond GIST—A Review

MYC amplification in angiosarcoma depends on etiological/clinical subgroups – Diagnostic and prognostic value

Contact Info

Product

Resources

About